3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
11
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
3
HER2-positive Breast Cancer
3
Colorectal Neoplasms
3
Advanced Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
HER2 Overexpression
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
42
Paclitaxel
26
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Nivolumab
16
fludarabine
15
Docetaxel
13
aldesleukin
12
Gemcitabine
11
Fulvestrant
11
veliparib
9
Bevacizumab
9
sargramostim
8
palbociclib
8
durvalumab
8
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
liposomal doxorubicin
7
atezolizumab
7
Surveys and Questionnaires
7
Ipilimumab
7
Blood Specimen Collection
7
niraparib
6
avelumab
6
Taxes
6
Specimen Handling
6
Interleukin-2
6
Fluorouracil
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
Breast
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled